From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants.


Journal

Gene
ISSN: 1879-0038
Titre abrégé: Gene
Pays: Netherlands
ID NLM: 7706761

Informations de publication

Date de publication:
10 Mar 2022
Historique:
received: 01 12 2021
accepted: 20 12 2021
pubmed: 7 1 2022
medline: 8 2 2022
entrez: 6 1 2022
Statut: ppublish

Résumé

Coronavirus-related Severe Acute Respiratory Syndrome (SARS-CoV) in 2002/2003, Middle-East Respiratory Syndrome (MERS-CoV) in 2012/2013, and especially the current 2019/2021 Severe Acute Respiratory Syndrome-2 (SARS-CoV-2) affected negatively the national health systems' endurance worldwide. SARS-Cov-2 virus belongs to lineage b of beta-CoVs demonstrating a strong phylogenetic similarity with BatCoVRaTG13 type. Spike (S) glycoprotein projections -consisting of two subunits S1/S2- provide a unique crown-like formation (corona) on virion's surface. Concerning their functional role, S1 represents the main receptor-binding domain (RBD), whereas S2 is involved in the virus-cell membrane fusion mechanism. On Nov 26th 2021, WHO designated the new SARS-CoV-2 strain - named Omicron, from letter ''όμικρον'' in the Greek alphabet - as a variant of concern (B.1.1529 variant). Potentially this new variant is associated with high transmissibility leading to elevated infectivity and probably increased re-infection rates. Its impact on morbidity/mortality remains under investigation. In the current paper, analyzing and comparing the alterations of SARS-CoV-2 S RNA sequences in the defined variants (Alpha to Omicron), we observed some interesting findings regarding the S1-RBD/S2 mutation/deletion equilibrium that maybe affect and modify its activity.

Identifiants

pubmed: 34990799
pii: S0378-1119(21)00729-0
doi: 10.1016/j.gene.2021.146134
pmc: PMC8725615
pii:
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

146134

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Références

J Hum Genet. 2020 Dec;65(12):1075-1082
pubmed: 32699345
Nature. 2020 Sep;585(7824):174-177
pubmed: 32901123
Cell Host Microbe. 2021 Mar 10;29(3):477-488.e4
pubmed: 33535027
Genomics. 2021 Jan;113(1 Pt 2):1221-1232
pubmed: 33007398
Cell Rep. 2021 Jan 12;34(2):108630
pubmed: 33417835
Euro Surveill. 2021 Jan;26(1):
pubmed: 33413740
Cell. 2020 Aug 20;182(4):794-795
pubmed: 32697970
mBio. 2020 Jul 21;11(4):
pubmed: 32694143
EBioMedicine. 2020 Dec;62:103112
pubmed: 33186810
Infect Genet Evol. 2021 Sep;93:104971
pubmed: 34146731
Virus Res. 2020 Oct 2;287:198098
pubmed: 32687861
Euro Surveill. 2021 Jan;26(3):
pubmed: 33478625
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Pathol Oncol Res. 2020 Oct;26(4):2823-2825
pubmed: 32333199
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Nat Microbiol. 2020 Oct;5(10):1185-1191
pubmed: 32908214
Gene. 2020 Oct 20;758:144944
pubmed: 32628976
Pathol Oncol Res. 2020 Oct;26(4):2839-2841
pubmed: 32691391
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
Elife. 2021 Feb 11;10:
pubmed: 33570490
RNA Biol. 2011 Mar-Apr;8(2):270-9
pubmed: 21593585
J Med Virol. 2020 Sep;92(9):1427-1429
pubmed: 32270884
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Infect Drug Resist. 2021 Jun 14;14:2187-2192
pubmed: 34163183
Nature. 2013 Nov 28;503(7477):535-8
pubmed: 24172901
Front Mol Biosci. 2021 Apr 20;8:654866
pubmed: 33959636
Viruses. 2021 May 27;13(6):
pubmed: 34071984
J Med Virol. 2020 Jun;92(6):667-674
pubmed: 32167180
Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165878
pubmed: 32544429
Nat Rev Immunol. 2021 Feb;21(2):73-82
pubmed: 33340022
Genes Dis. 2020 Dec;7(4):542-550
pubmed: 32363223
PLoS Biol. 2018 Jun 28;16(6):e2006459
pubmed: 29953453
Infect Genet Evol. 2021 Jul;91:104832
pubmed: 33812037
Nature. 2021 Jan;589(7840):125-130
pubmed: 32906143
Cell. 2021 Apr 15;184(8):2201-2211.e7
pubmed: 33743891
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Lancet. 2021 Feb 6;397(10273):462
pubmed: 33549181
Antiviral Res. 2020 Apr;176:104742
pubmed: 32057769
Lancet. 2020 Aug 29;396(10251):603-611
pubmed: 32822564
FEBS Lett. 2021 May;595(10):1454-1461
pubmed: 33728680
Cell Host Microbe. 2020 Mar 11;27(3):325-328
pubmed: 32035028
Front Immunol. 2020 Oct 02;11:579250
pubmed: 33123165
EMBO J. 2020 May 18;39(10):e105114
pubmed: 32246845
Clin Microbiol Infect. 2021 Aug;27(8):1109-1117
pubmed: 34015535
PLoS Biol. 2018 Aug 13;16(8):e3000003
pubmed: 30102691
Cell. 2020 Sep 3;182(5):1284-1294.e9
pubmed: 32730807
Infect Genet Evol. 2020 Nov;85:104457
pubmed: 32659347
Cell. 2020 Jul 23;182(2):417-428.e13
pubmed: 32526208
Nat Med. 2020 May;26(5):681-687
pubmed: 32327758
J Transl Med. 2020 Apr 22;18(1):179
pubmed: 32321524
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Science. 2005 Oct 28;310(5748):676-9
pubmed: 16195424
Front Med (Lausanne). 2021 May 07;8:636532
pubmed: 34026780
Science. 2021 Mar 12;371(6534):1139-1142
pubmed: 33536258
Cell Mol Life Sci. 2016 Dec;73(23):4433-4448
pubmed: 27392606
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508

Auteurs

Vasileios Papanikolaou (V)

1ST ENT Department, Hippocration Hospital, University of Athens, Athens, Greece.

Aris Chrysovergis (A)

1ST ENT Department, Hippocration Hospital, University of Athens, Athens, Greece.

Vasileios Ragos (V)

Dept of Maxillofacial, Medical School, University of Ioannina, Greece.

Evangelos Tsiambas (E)

Dept of Maxillofacial, Medical School, University of Ioannina, Greece; Department of Cytology, Molecular Unit, 417 Veterans Army Hospital (NIMTS), Athens, Greece. Electronic address: tsiambasecyto@yahoo.gr.

Spyros Katsinis (S)

Department of Otorhinolaryngology, Thoracic Diseases General Hospital "Sotiria", Athens, Greece.

Arezina Manoli (A)

Department of Otorhinolaryngology, Thoracic Diseases General Hospital "Sotiria", Athens, Greece.

Sotirios Papouliakos (S)

Department of Otolaryngology General Hospital ''Gennimatas'', Athens, Greece.

Dimitrios Roukas (D)

Department of Psychiatry, 417 Veterans Army Hospital (NIMTS), Athens, Greece.

Stylianos Mastronikolis (S)

Department of Ophthalmology, Medical School, University of Patras, Patras, Greece.

Dimitrios Peschos (D)

Department of Physiology, Medical School, University of Ioannina, Greece.

Anna Batistatou (A)

ENT Department, Medical School, University of Patras, Greece.

Efthimios Kyrodimos (E)

1ST ENT Department, Hippocration Hospital, University of Athens, Athens, Greece.

Nicholas Mastronikolis (N)

Department of Pathology, Medical School, University of Ioannina, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH